Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: L15 • 2019 ACR/ARP Annual Meeting
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial
David Isenberg¹, Richard Furie ², Nicholas Jones ³, Pascal Guibord ⁴, Joshua Galanter ⁵, Chin Lee ³, Anna McGregor ³, Balazs Toth ³, Julie Rae ³, Olivia Hwang ³, Pedro Miranda ⁶, Viviane de Souza ⁷, Juan Jaller-Raad ⁸, Anna Maura Fernandes ⁹, Rodrigo Garcia Salinas ¹⁰, Leslie Chinn ³, Michael Townsend ¹¹, Alyssa Morimoto ³ and Katie Tuckwell ¹², ¹University College London, London, United Kingdom, ²Northwell Health, Great Neck, NY, ³Genentech, Inc., South San Francisco, California, ⁴Hoffmann-La Roche Limited, Mississauga, Canada, ⁵Genentech, Inc., SOUTH SAN FRANCISCO, ⁶Centro Estudios Reumatologicos, Santiago, Chile, ⁷Centro Mineiro de Pesquisas, Juiz de Fora, Minas Gerais, Brazil, ⁸Centro de Reumatologia y Ortopedia, Cimedical, Barranquilla, Colombia, ⁹Mario Covas Hospital, Santo Andre, Sao Paulo, Brazil, ¹⁰Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, ¹¹Genentech, Inc., San Fransisco, ¹²Genentech, Inc., South San Francisco, CA
Background/Purpose: Fenebrutinib (GDC-0853, FEN) is an oral, non-covalent, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK) in clinical development for autoimmune diseases. The efficacy,…
Abstract Number: L18 • 2019 ACR/ARP Annual Meeting
A Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): Results of a Phase 2b Study
Di Wu¹, Jing Li ², Dong Xu ², Wenxiang Wang ³, Lin Li ⁴, Jianmin Fang ³ and Fengchun Zhang ⁵, ¹Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ²Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Beijing, China (People's Republic), ³RemeGen, Ltd., Yantai, China (People's Republic), ⁴RemeGen, Ltd., Beijing, China (People's Republic), ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (People's Republic)
Background/Purpose: Telitacicept, also named RC18, is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and…
Abstract Number: 136 • 2019 ACR/ARP Annual Meeting
Identifying Phenotypes of Patients with Antiphospholipid Antibodies: Results from a Cluster Analysis in a Large Cohort of Patients
Savino Sciascia¹, Massimo Radin ², Irene Cecchi ², Maria Laura Bertolaccini ³, Tiziana Bertero ², Elena Rubini ², Antonella Vaccarino ², Mario Bazzan ², Osvaldo Giachino ², Simone Baldovino ², Daniela Rossi ², Giulio Mengozzi ² and Dario Roccatello ², ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ²University of Turin, Turin, Italy, ³King's College London, London, United Kingdom
Background/Purpose: In this study, we sought to perform an unsupervised hierarchical clustering analysis in a large cohort of antiphospholipid antibodies (aPL) positive patients, to identify…
Abstract Number: 679 • 2019 ACR/ARP Annual Meeting
Longitudinal Changes in Manifestations of SLE
Amanda Eudy¹, Jennifer Rogers ¹, Raeann Whitney ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, David Pisetsky ², Rebecca Sadun ¹, Kai Sun ¹ and Megan Clowse ¹, ¹Duke University, Durham, ²Duke University, Durham VAMC, Durham
Background/Purpose: Our group has developed a conceptual model to categorize SLE manifestations into two dimensions termed Type 1 and Type 2. Type 1 SLE consists…
Abstract Number: 940 • 2019 ACR/ARP Annual Meeting
Response to Placebo in Randomized Clinical Trials with Biologics in Non-renal, Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Pooled Analysis
Konstantinos Tselios¹, Laura Wakani ², Dafna Gladman ³, Jiandong Su ⁴ and Murray Urowitz ⁴, ¹University Health Network, University of Toronto, Toronto, Canada, ²University Health Network, Toronto, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Most randomized controlled trials (RCTs) with biologic medicines in systemic lupus erythematosus (SLE) failed to reach their respective end-points with the rates of the…
Abstract Number: 1098 • 2019 ACR/ARP Annual Meeting
Epidemiology and Mortality of SLE (Systemic Lupus Erythematosus) in Hungary Based on a Nationwide Retrospective Claims Database Study
Melinda Kedves¹, Fruzsina Kósa ², Péter Takács ², Péter Kunovszki ², Jennifer Lofland ³ and György Nagy ⁴, ¹Hospital of Bács-Kiskun County, Department of Rheumatology, Kecskemét, Bacs-Kiskun, Hungary, ²Janssen, GCSO, Budapest, Budapest, Hungary, ³Janssen Scientific Affairs, LLC, Spring House, PA, ⁴Buda Hospital of the Hospitaller Order of Saint John of God, Department of Rheumatology, Budapest, Budapest, Hungary
Background/Purpose: There is little evidence in Hungary on the real incidence, prevalence and mortality of systemic lupus erythematosus (SLE) that is based on a robust…
Abstract Number: 1563 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease in Patients with Systemic Lupus Erythematosus: Who Should We Screen?
Muhsen Al-ani¹, Bobby Kwanghoon Han ² and Gregory c Gardner ³, ¹University of Washington, seattle, WA, ²University of Washington, seattle, ³University of Wasshington, seattle
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease with a variety of clinical manifestations but interestingly interstitial lung disease (ILD) is rare. The literature to…
Abstract Number: 1606 • 2019 ACR/ARP Annual Meeting
Association of African- American Ethnicity and Smoking Status and Total and Individual Damage Index in Systemic Lupus Erythematosus
Romy Kallas¹, Jessica Li ¹ and Michelle Petri ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Smoking and African- American ethnicity are risk factors for systemic lupus erythematosus (SLE). Smoking has been associated with increased prevalence of SLE, increased disease…
Abstract Number: 1767 • 2019 ACR/ARP Annual Meeting
Biomarker Profiling Reveals Novel Mechanistic Insights into Ustekinumab Therapeutic Responses in Systemic Lupus Erythematosus
Matteo Cesaroni¹, Loqmane Seridi ¹, Jarrat Jordan ¹, Kristen Sweet ¹, Keying Ma ¹, Carol Franks ¹, Jessica Schreiter ¹, Peter Lipsky ², Ronald van Vollenhoven ³, Bevra Hahn ⁴, Shawn Rose ¹, Frédéric Baribaud ¹, Matthew Loza ¹, Kim Campbell ¹ and George Tsokos ⁵, ¹Janssen Research & Development, LLC, Spring House, PA, ²AMPEL BioSolutions, LLC, Charlottesville, VA, ³Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁴University of California, Los Angeles, CA, ⁵Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease that causes progressive organ damage. The cytokines type I interferon (IFN-I), IL-12 and IL-23 have…
Abstract Number: 2027 • 2019 ACR/ARP Annual Meeting
Dysregulation of Granulopoiesis in Systemic Lupus Erythematosus
Neelakshi R. Jog¹, Teresa Aberle ¹, Cristina Arriens ², Stefania Gallucci ³ and Judith James ², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Lewis Katz School of Medicine, Temple University, Philadelphia, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production and periods of elevated disease activity. Recent studies indicate that along…
Abstract Number: 2293 • 2019 ACR/ARP Annual Meeting
Pregnancy in Patients with Systemic Lupus Erythematosus After Cyclophosphamide Therapy
Mitali Sen¹, Anu Kurl ¹, Tejal Vashi ² and Arezou Khosroshahi ¹, ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects females of reproductive age. Cyclophosphamide, an alkylating agent, labelled category D for pregnancy, is used for induction in…
Abstract Number: 2539 • 2019 ACR/ARP Annual Meeting
Patient Perception of Benefit and Risks Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus (SLE)
Sooyeon Kwon¹, Jessica Farrell ², Sarfaraz Hasni ³ and Shubhasree Banerjee ², ¹The Center For Rheumatology, Loudonville, NY, ²The Center for Rheumatology, LLC, Albany, NY, ³NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: Hydroxychloroquine (HCQ) is recommended in all patients with systemic lupus erythematosus (SLE). Studies suggest that a significant proportion of subjects are non-adherent to daily…
Abstract Number: 2736 • 2019 ACR/ARP Annual Meeting
Mucosal-associated Invariant T Cells Can Be Therapeutically Targeted in Lupus
Goh Murayama¹, Asako Chiba ², Tomohiro Mizuno ³, Atsushi Nomura ², Taiga Kuga ⁴, HIrofumi Amano ⁴, Ken Yamaji ⁴, Naoto Tamura ⁴ and Sachiko Miyake ², ¹Department of Internal Medicine and Rhumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Immunlogy, Juntendo University School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by the nonpolymorphic MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain:…
Abstract Number: 2882 • 2019 ACR/ARP Annual Meeting
Prospective Demonstration That Attainment of the Lupus Low Disease Activity State Is Associated with Improved Health Related Quality of Life
Vera Golder¹, Molla Huq ², Rangi Kandane-Rathnayake ³, Worawit Louthrenoo ⁴, Shue Fen Luo ⁵, Yeong-Jian Wu ⁵, Aisha Lateef ⁶, Sargunan Sockalingam ⁷, Sandra Navarra ⁸, Leonid Zamora ⁹, Laniyati Hamijoyo ¹⁰, Yasuhiro Katsumata ¹¹, Masayoshi Harigai ¹², Madelynn Chan ¹³, Sean O'Neill ¹⁴, Fiona Goldblatt ¹⁵, Chak Sing Lau ¹⁶, Zhanguo Li ¹⁷, Alberta Hoi ¹⁸, Mandana Nikpour ¹⁹ and Eric Morand ¹, ¹Monash University, Melbourne, Victoria, Australia, ²University of Melbourne, Melbourne, Australia, ³Monash University, Melbourne, Australia, ⁴Chiang Mai University Hospital, Chiang Mai, Thailand, ⁵Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), ⁶National University Hospital, Singapore, Singapore, ⁷University of Malaya, Kuala Lumpur, Malaysia, ⁸University of Santo Tomas Hospital, Manila, Philippines, ⁹Santo Tomas Hospital, Manila, Philippines, ¹⁰Padjadjaran University, Bandung, Indonesia, ¹¹Tokyo Women's University, Tokyo, Japan, ¹²Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ¹³Tan Tock Seng Hospital, Singapore, Singapore, ¹⁴University of New South Wales, Sydney, Australia, ¹⁵Royal Adelaide Hospital, Adelaide, Australia, ¹⁶Hong Kong University, Hong Kong, Hong Kong, ¹⁷Peking University People’s Hospital, Beijing, China (People's Republic), ¹⁸School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia, ¹⁹St Vincent's Hospital, Melbourne; The University of Melbourne, Melbourne, Australia
Background/Purpose: The Lupus Low Disease Activity State (LLDAS) is a treatment endpoint for SLE that has been shown in prospective validation studies to be associated…
Abstract Number: 245 • 2019 ACR/ARP Annual Meeting
Comorbidities, Health Care Utilization, and Cost of Care in Systematic Lupus Erythematous Increase with Disease Severity During 1 Year Before and After Diagnosis: A Real-World Cohort Study in the United States, 2004–2015
Miao Jiang¹, Aimee Near ², Barnabas Desta ¹, Xia Wang ¹ and Edward Hammond ¹, ¹AstraZeneca, Gaithersburg, MD, ²IQVIA, Durham, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with high economic burden. This real-world study assessed health care resource utilization (HRU) and costs in a US…

1
2
3
…
20
Next Page »